Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Laura Svajda"'
Autor:
Sára Eszter Surguta, Marcell Baranyi, Laura Svajda, Mihály Cserepes, Ivan Ranđelović, Enikő Tátrai, Balázs Hegedűs, József Tóvári
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Lung cancer is the leading cause of cancer-related death globally. Metastasis is the most common reason of mortality in which hypoxia is suggested to have a pivotal role. However, the effect of hypoxia on the metastatic potential and migrato
Externí odkaz:
https://doaj.org/article/cb277a475cdd4d908f18552eefd4c861
Autor:
Laura Svajda, Ivan Ranđelović, Sára Eszter Surguta, Marcell Baranyi, Mihály Cserepes, József Tóvári
Publikováno v:
Biomedicine & Pharmacotherapy, Vol 180, Iss , Pp 117601- (2024)
The poor vascularization of solid tumors results in oxygen-deprived areas within the tumor mass. This phenomenon is defined as tumor hypoxia and is considered to be a major contributor to tumor progression in breast and ovarian cancers due to hypoxia
Externí odkaz:
https://doaj.org/article/1480e2d9125d4a52adbeb977b25a2137
Autor:
Marco Zambra, Ivan Ranđelović, Francesco Talarico, Adina Borbély, Laura Svajda, József Tóvári, Gábor Mező, Lizeth Bodero, Sveva Colombo, Federico Arrigoni, Elettra Fasola, Silvia Gazzola, Umberto Piarulli
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Antibody-Drug Conjugates (ADCs) and Small Molecule-Drug Conjugates (SMDCs) represent successful examples of targeted drug-delivery technologies for overcoming unwanted side effects of conventional chemotherapy in cancer treatment. In both strategies,
Externí odkaz:
https://doaj.org/article/8398d4cb126548328281d797762b4133
Autor:
Mihály Cserepes, Györgyi A. Nelhűbel, Mónika Meilinger-Dobra, Adrienn Herczeg, Dóra Türk, Zita Hegedűs, Laura Svajda, Erzsébet Rásó, Andrea Ladányi, Kristóf György Csikó, István Kenessey, Árpád Szöőr, György Vereb, Éva Remenár, József Tóvári
Publikováno v:
Cancers; Volume 14; Issue 10; Pages: 2407
Background: Head and neck squamous cell carcinomas (HNSCCs) are among the most abundant malignancies worldwide. Patients with recurrent/metastatic disease undergo combination chemotherapy containing cetuximab, the monoclonal antibody used against the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::490244a9d10a8cdec4a3984bcd034571